Back to Authors

Kantarci, Kejal

https://orcid.org/0000-0002-8001-2081

Mayo Clinic

Mayo Clinic

Citations 648

O2–02–07: Hippocampal diffusivity on DTI differ between amnestic and non‐amnestic MCI
Avula, Ramesh, Przybelski, Scott A. , Weigand, Stephen D. , Petersen, Ronald C. , Kantarci, Kejal , Boeve, Bradley F. , Knopman, David S. , Smith, Glenn E. , Vemuri, Prashanthi , Jack, Clifford R.

Alzheimer's & Dementia | June 4, 2007 | Volume: 3 | Issue: 3S_Part_3 | Pages: No page available

10.1016/j.jalz.2007.04.041 Get It

IC–P–067: Patterns of decreased glucose metabolism differ among younger and older mild cognitive impairment patients; an FDG PET study
Senjem, Matthew L. , Kemp, Brad , Lowe, Val J. , Shiung, Maria, Petersen, Ronald, Ivnik, Robert J., Tangalos, Eric G., Kantarci, Kejal , Boeve, Bradley F. , Knopman, David S. , Smith, Glenn E. , Jack, Clifford R. , Senjem, Matthew L

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_22 | Pages: No page available

10.1016/j.jalz.2006.05.2272 Get It

IC–P–024: MRI, MRS and clinical correlates in posterior cortical atrophy and typical Alzheimer's disease
Whitwell, Jennifer L. , Drubach, Daniel A., Tang‐Wai, David F. , Petersen, Ronald C. , Josephs, Keith A. , Jack, Clifford R. , Kantarci, Kejal , Boeve, Bradley F. , Knopman, David S.

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_21 | Pages: No page available

10.1016/j.jalz.2006.05.2229 Get It

IC–102–04: 1H MR spectroscopy findings differ among mild cognitive impairment syndromes
Petersen, Ronald, Ivnik, Robert J., Angalos, Eric, Kantarci, Kejal , Boeve, Bradley F. , Knopman, David S. , Smith, Glenn E. , Jack, Clifford R.

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_21 | Pages: No page available

10.1016/j.jalz.2006.05.2193 Get It

P2–348: MRI, MRS and clinical correlates in posterior cortical atrophy and typical Alzheimer's disease
Whitwell, Jennifer L., Drubach, Daniel A., Tang‐Wai, David F. , Petersen, Ronald C. , Josephs, Keith A. , Whitwell, Jennifer , Jack, Clifford R. , Kantarci, Kejal , Boeve, Bradley F. , Knopman, David S.

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_11 | Pages: No page available

10.1016/j.jalz.2006.05.1188 Get It

P2–345: 1H MR spectroscopy findings differ among mild cognitive impairment syndromes
Petersen, Ronald, Ivnik, Robert J., Tangalos, Eric G., Kantarci, Kejal , Boeve, Bradley F. , Knopman, David S. , Smith, Glenn E. , Jack, Clifford R.

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_11 | Pages: No page available

10.1016/j.jalz.2006.05.1185 Get It

P2–198: Patterns of decreased glucose metabolism differ among younger and older mild cognitive impairment patients; an FDG PET study
Senjem, Matthew L. , Kemp, Brad , Lowe, Val J. , Shiung, Maria, Petersen, Ronald C. , Ivnik, Robert J., Tangalos, Eric G., Kantarci, Kejal , Boeve, Bradley F. , Knopman, David S. , Smith, Glenn E. , Jack, Clifford R. , Senjem, Matthew L

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_10 | Pages: No page available

10.1016/j.jalz.2006.05.1036 Get It

Role of biomarkers in studies of presymptomatic Alzheimer's disease
Morris, John C. , Kimberly, A., Quaid, Kimberly A., Kantarci, Kejal , Kaye, Jeffrey , Reiman, Eric M. , Klunk, William E. , Siemers, Eric , Kimberly, A., Holtzman, David M. , Kantarci, Kejal , Morris, John C

Alzheimer's & Dementia | December 19, 2005 | Volume: 1 | Issue: 2 | Pages: 145-151

10.1016/j.jalz.2005.09.013 Get It

BackgroundBiomarkers that have been developed largely for the study of patients with clinically diagnosed Alzheimer's disease (AD) can also be used in the study of cognitively normal individuals who may harbor underlying AD pathology.MethodsA meeting of invited experts on AD biomarkers was held on November 11 and 12, 2004 to review currently available data and to discuss unmet needs for biomarker research in presymptomatic AD.ResultsNeuroimaging biomarkers have been studied to some extent in subjects at risk for AD. These imaging techniques include volumetric magnetic resonance imaging and positron emission tomography using either fluorodeoxyglucose or newer ligands that bind directly to amyloid plaque. Similarly, biochemical measures from cerebrospinal fluid or other physiologic fluids are emerging as potentially useful tools. Such biomarkers may be used either as diagnostic tools or as indicators of disease severity when followed longitudinally. A clinical diagnosis of asymptomatic individuals using biomarkers and studies involving asymptomatic subjects may raise logistical and ethical concerns.ConclusionsThe technical development of biomarkers that are used for presymptomatic AD diagnosis and for longitudinally measuring disease severity is evolving rapidly. Ethical and privacy considerations must be made before such biomarkers can be applied routinely to asymptomatic populations.